Method of using attenuated bordetella strains
A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
1. A method for protecting a subject against disease caused by Bordetella infection, comprising administering to the subject in need of such treatment a live attenuated Bordetella pertussis strain comprising at least a mutated pertussis toxin (ptx) gene, a deleted or mutated dermonecrotic (dnt) gene, and a heterologous ampG gene replacing the Bordetella ampG gene, wherein the strain is able to colonize and induce protective immunity in the subject.
2. The method of claim 1 , wherein the Bordetella infection is a Bordetella pertussis infection.
3. The method of claim 1 , wherein the subject is a newborn or a child.
4. The method of claim 1 , wherein the live attenuated Bordetella strain is administered to the respiratory tract.
5. The method of claim 4 , wherein the live attenuated Bordetella strain is administered intranasally.
6. The method of claim 1 , wherein the live attenuated Bordetella strain is a BPZE1 strain deposited with the Collection Nationale de Culture Microorganismes as accession number 1-3585.
7. The method of claim 1 , wherein the live attenuated Bordetella strain expresses less than 5% residual tracheal cytotoxin (CTC) activity.